On assessing the presence of evaluation-time bias in progression-free survival in randomized trials

被引:5
|
作者
Kay, Richard [1 ]
Wu, Jane [2 ]
Wittes, Janet [3 ]
机构
[1] RK Stat Ltd, Great Longstone, England
[2] Genta Inc, Berkeley Hts, NJ USA
[3] Stat Collaborat, Washington, DC USA
关键词
progression-free survival; simulation; logrank test;
D O I
10.1002/pst.443
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Evaluation (or assessment)-time bias can arise in oncology trials that study progression-free survival (PFS) when randomized groups have different patterns of timing of assessments. Modelling or computer simulation is sometimes used to explore the extent of such bias; valid results require building such simulations under realistic assumptions concerning the timing of assessments. This paper considers a trial that used a logrank test where computer simulations were based on unrealistic assumptions that severely overestimated the extent of potential bias. The paper shows that seemingly small differences in assumptions can lead to dramatic differences in the apparent operating characteristics of logrank tests. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:213 / 217
页数:5
相关论文
共 50 条
  • [11] Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials
    Trippa, Lorenzo
    Wen, Patrick Y.
    Parmigiani, Giovanni
    Berry, Donald A.
    Alexander, Brian M.
    NEURO-ONCOLOGY, 2015, 17 (08) : 1106 - 1113
  • [12] Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials
    Lesan, Vadim
    Olivier, Timothee
    Prasad, Vinay
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [13] Progression-free survival as an end-point in clinical trials of biotherapeutic agents
    Bergmann, Lothar
    Hirschfeld, Steven
    Morris, Charles
    Palmeri, Sergio
    Stone, Andrew
    EJC SUPPLEMENTS, 2007, 5 (09): : 23 - 28
  • [14] Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer
    Gill, S.
    Berry, S.
    Biagi, J.
    Butts, C.
    Buyse, M.
    Chen, E.
    Jonker, D.
    Marginean, C.
    Samson, B.
    Stewart, J.
    Thirlwell, M.
    Wong, R.
    Maroun, J. A.
    CURRENT ONCOLOGY, 2011, 18 : S5 - S10
  • [15] Analysis of progression-free survival in oncology trials: Some common statistical issues
    Carroll, Kevin J.
    PHARMACEUTICAL STATISTICS, 2007, 6 (02) : 99 - 113
  • [16] Missing Data and Censoring in the Analysis of Progression-Free Survival in Oncology Clinical Trials
    Denne, J. S.
    Stone, A. M.
    Bailey-Iacona, R.
    Chen, T. -T.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2013, 23 (05) : 951 - 970
  • [17] Assessing temporal agreement between central and local progression-free survival times
    Zeng, Donglin
    Cornea, Emil
    Dong, Jun
    Pan, Jean
    Ibrahim, Joseph G.
    STATISTICS IN MEDICINE, 2015, 34 (05) : 844 - 858
  • [18] Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials
    Li, Ling
    Pan, Zhanyu
    CLINICAL BREAST CANCER, 2018, 18 (01) : 63 - 70
  • [19] Association between progression-free survival and patients' quality of life in cancer clinical trials
    Hwang, Thomas J.
    Gyawali, Bishal
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (07) : 1746 - 1751
  • [20] Quantifying the association between progression-free survival and overall survival in oncology trials using Kendall's τ
    Weber, Enya M.
    Titman, Andrew C.
    STATISTICS IN MEDICINE, 2019, 38 (05) : 703 - 719